12 November 2020

Systems and Instrumentation

Paris Region supports the development of the BEC SARS-CoV-2 diagnostic test

In order to support the development of BEC, an ultra-rapid diagnostic test for Covid-19, Paris Region has just awarded, as part of the PM'up Covid-19 call for projects, two grants for a total amount of € 400,000 to Bertin Technologies and Enalees, located respectively in Yvelines and Essonne.

Enalees Bertin Technologies have developed, in collaboration with the Institut Pasteur, an ultra-rapid diagnostic test to immediately isolate infected people as it delivers in the field, in less than 30 minutes, a more reliable result than saliva tests or antigenic.

Developed by Enalees, located on the biocluster site Genopole, & Bertin Technologies, it responds to the problems of laboratories congestion and can be integrated into the diagnostic systems of communities or companies, making possible to immediately identify and isolate an infected person. 

  • Its nasal sample is less invasive than the nasopharyngeal sample from conventional PCR tests.
  • The result is read using a pack that is easily transportable in any type of environment, even isolated.
  • The test is reimbursed by health insurance.

CNR certified (National Reference Center), the test is also referenced by the Ministry of Solidarity and Health on its Covid-19 platform (BEC SARS-CoV-2 RT-LAMP kit for human samples)

According to the report published by the CNR, the reliability of BEC test based on RT-LAMP technology records “performances similar to the reference technique” RT-PCR.

In accordance with the method recommended by the WHO (World Health Organization) and the HAS (Haute Autorité de Santé), the BEC test targets two SARS-CoV-2 genes and incorporates a positive control to validate the correct execution of the process, from the sampling to obtaining the result.

Laurent Thiery, president and co-founder of Enalees: This grant from the Paris Region has enabled Bertin Technologies and Enalees to accelerate the finalization of the development of BEC tests and to make progress on CE-IVD marking of the test for humans. This is a strong mark of confidence and interest that the Region sends through us to biotech companies in the Paris region ".

Bruno Vallayer, CEO of Bertin Technologies: The registration of the BEC test on the website of the Ministry of Health, following the evaluation by the CNR of Lyon, makes the BEC SARS-CoV-2 test for humans reimbursable by social security. It is to date the only rapid test, developed and manufactured in France that has been evaluated by the CNR, and it is an important step in its commercialization.